Tonix partners with GPO to secure TONMYA coverage for 35 million US commercial lives

Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp.

TNXP

0.00
  • Tonix Pharmaceuticals entered payer-coverage agreement effective May 1, 2026, with a group purchasing organization covering about 35 million US commercial lives, representing about 20% of US commercial market.
  • Deal expands access for TONMYA, Tonix fibromyalgia treatment launched commercially in November 2025, under standard utilization-management requirements.
  • Tonix also reported TONMYA covered under Medicaid in 38 states, reaching about 55 million lives, or 73% of US Medicaid lives.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605060700PRIMZONEFULLFEED9713941) on May 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.